<DOC>
	<DOCNO>NCT00950222</DOCNO>
	<brief_summary>The study prospective open trial conduct 4 center , design determine pharmacokinetic ( PK ) pharmacodynamic ( PD ) parameter imipenem , associate amikacin empirical therapy , impact microbiological clinical outcome patient Gram negative bacillus ( GNB ) ventilator-associated pneumonia ( VAP ) .</brief_summary>
	<brief_title>Impact Imipenem With Amikacin Pharmacokinetic Pharmacodynamic</brief_title>
	<detailed_description>Inappropriate initial antibiotherapy increase mortality many serious infection . This case ventilator-associated pneumonia , frequently occur intensive care unit ( ICU ) hospitalization , whose 48 first hour treatment decisive . It well establish pharmacokinetic pharmacodynamic parameter antibiotic correlate clinical microbiological effectiveness . However ICU patient , pharmacokinetic parameter antibiotic suffer great variation , bacteria responsible infection usually less sensitive antibiotic , especially Gram negative bacillus ( GNB ) . An important pharmacodynamic variability may occur initial phase antibiotic treatment , decisive infection 's outcome . We propose evaluate correlation pharmacokinetic pharmacodynamic profile empirical antibiotic therapy microbiological clinical outcome VAP .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Ventilator-Associated</mesh_term>
	<mesh_term>Imipenem</mesh_term>
	<mesh_term>Amikacin</mesh_term>
	<criteria>1 . Age ≥ 18 year 2 . Mechanical ventilation 48 hour 3 . Clinical suspicion VAP define new persistent radiological infiltrate one follow sign : purulent tracheal aspiration , temperature 38°3 high , leucocyte count &gt; 10000/ml 4 . Risk multi resistant bacteria define follow : least 6 day mechanical ventilation antibiotic treatment 15 previous day 5 . Distal pulmonary secretion sample obtain beforehand microbiological diagnosis bronchoalveolar lavage via bronchoscopy blind protected telescoping catheter via bronchoscopy blindly 6 . Presence GNB direct examination distal pulmonary secretion sample 7 . Realization preliminary medical examination . 8 Written inform consent patient relative . The consent may obtain enrollment patient able give consent relatives 1 . Time distal pulmonary secretion sample take 1st administration imipenem exceed 24 hour 2 . Pregnancy 3 . Severely impaired renal function ( creatinine clearance lower 10 mL/mn renal replacement therapy ) 4 . Allergy imipenem amikacin 5 . Treatment progress imipenem amikacin 6 . Death expect within 48 hour follow diagnosis VAP 7 . Myasthenia 8 . Simultaneous administration others aminoglycosides 9 . Association intravenous polymyxin botulinum toxin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Intensive care unit</keyword>
	<keyword>Ventilator associate pneumonia</keyword>
	<keyword>Gram negative bacillus infection</keyword>
	<keyword>Empirical antibiotic therapy</keyword>
	<keyword>Pharmacokinetic / pharmacodynamic</keyword>
	<keyword>Imipenem</keyword>
	<keyword>Amikacin</keyword>
	<keyword>Gram negative bacillus</keyword>
</DOC>